Merck Serono signs deal with Genea Biomedx for fertility treatment

28 May 2015

German life science and performance materials company Merck KGaA (MRK: DE) has entered into a global collaboration agreement with the fertility technologies expert Genea Biomedx, an Australian company, dedicated to advancing fertility science and helping couples create families.

With this partnership, Merck Serono, the biopharmaceutical business of Merck, and global market leader in drugs for assisted reproductive treatment (ART), receives global marketing and commercialization rights to Genea Biomedx’ product portfolio. This comprises the innovative Gavi, Geri and Gems product lines which are expected to receive CE mark in Europe shortly, as well as a joint development pipeline. Financial terms of the accord were not disclosed.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK